SMU-L11
SMU-L11 is a specific TLR7 agonist (EC50=0.024 μM), which recruits MyD88 adapter protein and activates downstream NF-κB and MAPK signaling pathways. In murine models, SMU-L11 significantly enhances immune cell activation and promotes the proliferation of CD4+ T and CD8+ T cells, thereby directly killing tumor cells and inhibiting tumor growth. SMU-L11 can be used for cancer research, and also has the potential for studying immune system diseases[1].
Product Specifications
UNSPSC
12352005
Target
MAPKAPK2 (MK2) ; NF-κB; Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/smu-l11.html
Purity
99.64
Solubility
10 mM in DMSO
Smiles
CCCCC1=NC2=C(N1CC3CCOC3)C4=CC=CC=C4N=C2N
Molecular Formula
C19H24N4O
Molecular Weight
324.42
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
TLR7
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cytokeratin, HMW (KRTH/1076), CF488A conjugate, 0.1mg/mL
